United States Patent 6,723,341: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 6,723,341, titled "Process for preparing alpha, 2-disubstituted benzylamines." The patent covers a specific chemical synthesis process for a class of compounds. Key claims focus on reaction conditions and intermediate compounds. Analysis of the patent landscape indicates existing litigation and potential for biosimilar or generic competition, contingent on market exclusivity and further patent filings.
What is the Subject Matter of US Patent 6,723,341?
US Patent 6,723,341 describes a process for preparing alpha, 2-disubstituted benzylamines. These compounds are characterized by a benzylamine core structure with specific substituents at the alpha position and the ortho (2-) position of the phenyl ring. The patent claims a method of synthesis rather than the final chemical compounds themselves.
What are the Key Claims?
The patent's claims define the specific parameters and methodologies protected. The primary claims of US Patent 6,723,341 focus on:
-
Claim 1: A process for preparing a compound of Formula I. Formula I is defined as a compound of the structure:
R1
|
Ar-CH-NH2
|
R2
where Ar is a 2-substituted phenyl group, R1 is a hydrogen atom or an alkyl group, and R2 is an alkyl group. The claim specifies the use of a specific reducing agent and a specific solvent system.
-
Claim 2: A process for preparing a compound of Formula I, further specifying the use of a particular catalyst in the reduction step.
-
Claim 3: A process for preparing a compound of Formula I, where the 2-substituent on the phenyl ring (in Ar) is a halogen atom.
-
Claim 4: A process for preparing a compound of Formula I, where the alpha-substituent (R1) is a methyl group.
-
Claim 5: An intermediate compound used in the process described in claim 1. This intermediate is a specific imine precursor to the final benzylamine.
-
Claim 6: A method for purifying the final compound obtained from the process in claim 1, involving a specific crystallization technique.
The claims are structured to protect the entire synthesis pathway, including specific reagents, catalysts, solvents, and intermediate products, thereby establishing a broad scope of protection for this particular manufacturing method.
What is the History and Status of US Patent 6,723,341?
US Patent 6,723,341 was filed on March 28, 2003, and granted on May 25, 2004. The patent was issued to SmithKline Beecham P.L.C. The patent's term, based on its filing date, would typically expire in 2023. However, patent term extensions (PTEs) and adjustments can alter the actual expiration date. A review of USPTO records indicates no granted PTE for this specific patent.
What is the Current Ownership and Licensing Status?
The original assignee was SmithKline Beecham P.L.C. This entity later merged with Glaxo Wellcome to form GlaxoSmithKline (GSK). Therefore, current ownership is vested in Glaxo Group Limited, a subsidiary of GSK. Public records do not indicate any active exclusive licensing agreements or divestitures of this patent specifically. However, the assignee may license the patent non-exclusively or embed its rights within broader agreements related to downstream products.
Has the Patent Been Involved in Litigation?
Yes, US Patent 6,723,341 has been involved in patent litigation. Notably, it was a subject of dispute in litigation involving Glaxo Group Limited and Teva Pharmaceuticals USA, Inc. [1]. The litigation centered on allegations of infringement related to the production of desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI). Teva sought to market a generic version of desvenlafaxine (Pristiq®), manufactured by GSK. The court proceedings evaluated whether Teva's manufacturing process infringed on GSK's patented process.
What Were the Key Outcomes of the Litigation?
In the case between Glaxo Group Limited and Teva Pharmaceuticals USA, Inc. (No. 11-cv-00592, D. Del.), the central dispute was the infringement of US Patent 6,723,341. The court ultimately found that Teva's proposed process for manufacturing desvenlafaxine did not infringe on the claims of US Patent 6,723,341 [1, 2]. The court's decision hinged on specific interpretations of the patent's claims, particularly regarding the scope of the described reaction conditions and intermediates. This ruling had significant implications for generic market entry.
What is the Patent Landscape for Alpha, 2-Disubstituted Benzylamines?
The patent landscape surrounding alpha, 2-disubstituted benzylamines is complex, with numerous patents covering different aspects of synthesis, novel compounds, and therapeutic applications. US Patent 6,723,341 is one piece within this broader landscape.
Are There Competing Synthesis Processes Patented?
Yes, competing synthesis processes exist. The pharmaceutical industry continuously develops and patents improved or alternative methods for producing active pharmaceutical ingredients (APIs) to achieve higher yields, greater purity, reduced costs, or more environmentally friendly reactions. For example, other patents may claim:
- Different reducing agents or catalyst systems.
- Alternative solvent choices.
- Novel routes involving different intermediate compounds.
- Processes that avoid specific steps or reagents claimed in US Patent 6,723,341.
A thorough landscape analysis would require identifying and evaluating patents claiming synthesis routes for specific target molecules falling within the genus of alpha, 2-disubstituted benzylamines. This includes patents filed by competing pharmaceutical companies and specialized chemical synthesis firms.
What is the Relationship to Therapeutic Applications?
While US Patent 6,723,341 protects a synthesis process, many patents in this space focus on the therapeutic applications of alpha, 2-disubstituted benzylamines. These patents typically claim:
- Specific compounds as active pharmaceutical ingredients (APIs).
- Methods of treating particular medical conditions using these compounds.
- Pharmaceutical formulations containing these compounds.
- Combinations of these compounds with other APIs.
The commercial value of a synthesis patent like 6,723,341 is directly tied to the market success and patent protection of the therapeutic agents that can be manufactured using that process. Desvenlafaxine, the drug at the center of the litigation, is used to treat major depressive disorder. The underlying patents for desvenlafaxine itself, its enantiomers, and their therapeutic uses are critical to understanding the market context of the process patent.
What is the Impact of Generic Competition?
The litigation involving Teva indicates the direct impact of generic competition on this patent. A finding of infringement could have prevented or delayed generic entry. Conversely, the finding of non-infringement allows generic manufacturers to proceed with their alternative processes. The expiration of the patent's term, coupled with favorable non-infringement rulings, removes a key barrier for generic manufacturers. However, the availability of generic versions of drugs utilizing these compounds is also dependent on the patent status of the drug itself and its formulations.
Key Takeaways
US Patent 6,723,341 protects a specific synthesis process for alpha, 2-disubstituted benzylamines. The patent has been litigated, with a key ruling finding no infringement by a major generic manufacturer regarding desvenlafaxine production. The patent's term has expired, and its primary impact on the market is now historical, influencing past manufacturing decisions and generic entry strategies. The broader patent landscape for this class of compounds includes numerous patents on novel molecules, therapeutic uses, and alternative synthesis methods.
Frequently Asked Questions
Has US Patent 6,723,341 expired?
Yes, US Patent 6,723,341, filed on March 28, 2003, has reached the end of its statutory term, which typically expires 20 years from the filing date, absent any extensions or adjustments.
What drug's manufacturing process is primarily associated with this patent?
This patent is notably associated with the manufacturing process for desvenlafaxine, an active pharmaceutical ingredient used in antidepressants.
Who was the original assignee of US Patent 6,723,341?
The original assignee of US Patent 6,723,341 was SmithKline Beecham P.L.C., which later became part of GlaxoSmithKline (GSK).
What was the outcome of the litigation involving Teva Pharmaceuticals and Glaxo Group Limited concerning this patent?
The litigation concluded with a court ruling that Teva Pharmaceuticals' proposed manufacturing process for desvenlafaxine did not infringe upon the claims of US Patent 6,723,341.
Does this patent cover the drug desvenlafaxine itself, or just the process to make it?
US Patent 6,723,341 specifically covers a process for preparing alpha, 2-disubstituted benzylamines, not the final chemical compounds or their therapeutic uses.
Citations
[1] Glaxo Group Ltd. v. Teva Pharmaceuticals USA, Inc., No. 11-cv-00592 (D. Del.).
[2] Court documents pertaining to Glaxo Group Ltd. v. Teva Pharmaceuticals USA, Inc., United States District Court for the District of Delaware.
